• Policy
• Industry unsatisfied with the proposed PVA improvements
• by Lee, Tak-Sun Mar 10, 2023 05:50am

• Company
• Myelofibrosis New Drug Inrebic
• by Eo, Yun-Ho Mar 10, 2023 05:50am

• Company
• Enbrel's share is 44% and Herceptin's share is 37%
• by Kim, Jin-Gu Mar 10, 2023 05:50am

• Policy
• Dupixent, Cibinqo, Rinvoq to be reimb for pediatric AD in 1H
• by Lee, Tak-Sun Mar 10, 2023 05:49am

• Company
• Sales of Kisqali surge, Ibrance decline
• by Jung, Sae-Im Mar 9, 2023 06:00am

• Policy
• Multiple myeloma CAR-T therapeutic agent CARVYKTI, imminent
• by Lee, Hye-Kyung Mar 9, 2023 06:00am

• Company
• Childhood dementia Tx Xenpozyme to soon land in KOR
• by Eo, Yun-Ho Mar 9, 2023 06:00am

• Company
• Hemlibra is also effective for mild and secondary hemophilia
• by Kim, Jin-Gu Mar 9, 2023 06:00am

• Policy
• Gov expands SGLT-2 diabetes drug combi benefit from April
• by Lee, Jeong-Hwan Mar 8, 2023 05:53am

• Company
• Becton Dickinson achieves a 90% customer satisfaction rate
• by Eo, Yun-Ho Mar 8, 2023 05:53am